Answers are grounded in this paper and cite their sources.
// Sung Yong Oh 1 , Aesun Shin 2 , Seong-Geun Kim 3 , Jung-Ah Hwang 4 , Seung Hyun Hong 4 , Yeon-Su Lee 4 , Hyuk-Chan Kwon 5 1 Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea 2 Department of Preventive Medicine, Seoul National University, Korea 3 Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea 4 Cancer Genomics Branch, Research Institute, National Cancer Center, Goyang, Gyeonggi-do, Korea 5 Sillajen Inc., Busan, Korea Correspondence to: Yeon-Su Lee, email: yslee2@ncc.re.kr Hyuk-Chan Kwon, email: hckwon@sillajen.com Keywords: insulin-like growth factor, polymorphism, gastric cancer Received: January 08, 2016 Accepted: April 11, 2016 Published: April 29, 2016 ABSTRACT The insulin-like growth factor (IGF) axis plays a crucial role in proliferation, differentiation, migration, angiogenesis, and apoptosis. The present study evaluated the associations between IGF axis single-nucleotide polymorphisms (SNPs) and clinical outcomes in advanced gastric cancer (AGC) patients treated with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX). A total of 190 patients undergoing FOLFOX chemotherapy for AGC were considered eligible for this study. Forty-four SNPs of 10 IGF axis genes were genotyped. Levels of serum IGF1 were measured using enzyme-linked immunoassays. SNPs of the IGF1R (rs12423791), and IGF1 (rs2162679, rs5742612, rs35767) genes were significantly associated with tumor response to FOLFOX. SNPs of rs4619 and rs17847203 were significantly associated with PFS (hazard ratio [HR] 0.575, 95% CI 0.385–0.858, P = 0.007; and HR 2.530, 95% CI 1.289–4.966, P = 0.007; respectively). SNPs of rs2872060 were significantly associated with OS—OS was shorter in patients carrying the TT variant than in those with the GG/GT genotypes (HR, 1.708, 95% CI 1.024–2.850, P = 0.040). The GT genotype of rs12847203 was also identified as an independent prognostic factor (HR 2.087, 95% CI 1.070–4.069, P = 0.031). These results suggest that IGF axis-pathway SNPs could be used as prognostic biomarkers of the outcome of FOLFOX chemotherapy in AGC patients. This information may facilitate identification of population subgroups that could benefit from IGF1R-targeted agents.
No takes yet. Share an insight, caveat, or question.
Oh et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: